Profound Medical preliminary Q3 2025 results

Profound Medical Corp. filed a current report to note that it issued a press release on October 7, 2025 announcing certain preliminary unaudited financial results for the three months ended September 30, 2025 and providing a business update.

Rhea-AI Filing Summary

Profound Medical Corp. filed a current report to note that it issued a press release on October 7, 2025 announcing certain preliminary unaudited financial results for the three months ended September 30, 2025 and providing a business update. The press release is furnished as Exhibit 99.1 under Item 2.02, which covers results of operations and financial condition. The company states that this information, including Exhibit 99.1, is furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Profound Medical Corp. (PROF) disclose in this 8-K filing?

Profound Medical Corp. reported that it issued a press release announcing certain preliminary unaudited financial results for the three months ended September 30, 2025 and provided a business update, which is furnished as Exhibit 99.1.

Which financial period do the preliminary results for Profound Medical (PROF) cover?

The preliminary unaudited financial results described by Profound Medical Corp. relate to the three months ended September 30, 2025.

Is the Profound Medical Corp. preliminary financial information considered filed with the SEC?

No. The company states that the information in Item 2.02, including Exhibit 99.1, is furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934.

What exhibit is attached to Profound Medical Corp.’s (PROF) 8-K about preliminary results?

Exhibit 99.1 is a press release dated October 7, 2025, and Exhibit 104 is the cover page interactive data file embedded within the Inline XBRL document.

On which exchange are Profound Medical Corp. (PROF) shares listed?

Profound Medical Corp.’s common shares trade on The Nasdaq Stock Market under the trading symbol PROF.

Who signed the Profound Medical Corp. 8-K reporting preliminary results?

The report was signed on behalf of Profound Medical Corp. by Rashed Dewan, Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/07/2025 - 08:06 AM EDT Learn about SEC filing dates

False000162880800016288082025-10-072025-10-07iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  October 7, 2025

_______________________________

PROFOUND MEDICAL CORP.

(Exact name of registrant as specified in its charter)

_______________________________

Ontario, Canada	001-39032	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2400 Skymark Avenue, Unit 6

Mississauga, Ontario, Canada L4W 5K5

(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: 647-476-1350

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares	PROF	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On October 7, 2025, Profound Medical Corp. (the “Company”) issued a press release to announce certain of its preliminary unaudited financial results for the three months ended September 30, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1.

The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated October 7, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROFOUND MEDICAL CORP.
Date: October 7, 2025	By:	/s/ Rashed Dewan
		Rashed Dewan
		Chief Financial Officer